Predicting Circulating CA125 Levels among Healthy Premenopausal Women.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
16
10
2018
revised:
16
01
2019
accepted:
27
03
2019
pubmed:
6
4
2019
medline:
7
8
2020
entrez:
6
4
2019
Statut:
ppublish
Résumé
Cancer antigen 125 (CA125) is the most promising ovarian cancer screening biomarker to date. Multiple studies reported CA125 levels vary by personal characteristics, which could inform personalized CA125 thresholds. However, this has not been well described in premenopausal women. We evaluated predictors of CA125 levels among 815 premenopausal women from the New England Case Control Study (NEC). We developed linear and dichotomous (≥35 U/mL) CA125 prediction models and externally validated an abridged model restricting to available predictors among 473 premenopausal women in the European Prospective Investigation into Cancer and Nutrition Study (EPIC). The final linear CA125 prediction model included age, race, tubal ligation, endometriosis, menstrual phase at blood draw, and fibroids, which explained 7% of the total variance of CA125. The correlation between observed and predicted CA125 levels based on the abridged model (including age, race, and menstrual phase at blood draw) had similar correlation coefficients in NEC ( We identified a combination of factors associated with CA125 levels in premenopausal women. Our model could be valuable in identifying healthy women likely to have elevated CA125 and consequently improve its specificity for ovarian cancer screening.
Sections du résumé
BACKGROUND
Cancer antigen 125 (CA125) is the most promising ovarian cancer screening biomarker to date. Multiple studies reported CA125 levels vary by personal characteristics, which could inform personalized CA125 thresholds. However, this has not been well described in premenopausal women.
METHODS
We evaluated predictors of CA125 levels among 815 premenopausal women from the New England Case Control Study (NEC). We developed linear and dichotomous (≥35 U/mL) CA125 prediction models and externally validated an abridged model restricting to available predictors among 473 premenopausal women in the European Prospective Investigation into Cancer and Nutrition Study (EPIC).
RESULTS
The final linear CA125 prediction model included age, race, tubal ligation, endometriosis, menstrual phase at blood draw, and fibroids, which explained 7% of the total variance of CA125. The correlation between observed and predicted CA125 levels based on the abridged model (including age, race, and menstrual phase at blood draw) had similar correlation coefficients in NEC (
CONCLUSIONS
We identified a combination of factors associated with CA125 levels in premenopausal women.
IMPACT
Our model could be valuable in identifying healthy women likely to have elevated CA125 and consequently improve its specificity for ovarian cancer screening.
Identifiants
pubmed: 30948451
pii: 1055-9965.EPI-18-1120
doi: 10.1158/1055-9965.EPI-18-1120
pmc: PMC6548604
mid: NIHMS1526274
doi:
Substances chimiques
CA-125 Antigen
0
MUC16 protein, human
0
Membrane Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1076-1085Subventions
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : K07 CA222159
Pays : United States
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R35 CA197605
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA193965
Pays : United States
Organisme : Cancer Research UK
ID : C570/A16491
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA158119
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Hum Reprod. 1999 Feb;14(2):566-70
pubmed: 10100011
Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):489-93
pubmed: 11352859
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Hum Reprod. 1992 Jan;7(1):35-8
pubmed: 1532397
Hum Reprod Update. 1995 Mar;1(2):173-87
pubmed: 15726771
Int J Gynecol Cancer. 2005 Sep-Oct;15(5):679-91
pubmed: 16174214
Am J Epidemiol. 1992 May 15;135(10):1114-26; discussion 1127-36
pubmed: 1632423
Stat Methods Med Res. 2007 Jun;16(3):219-42
pubmed: 17621469
Gynecol Oncol. 2008 Sep;110(3):383-9
pubmed: 18586313
Obstet Gynecol. 2011 May;117(5):1042-50
pubmed: 21471855
JAMA. 2011 Jun 8;305(22):2295-303
pubmed: 21642681
J Natl Cancer Inst. 2012 Dec 19;104(24):1905-16
pubmed: 23221879
Obstet Gynecol. 1990 Sep;76(3 Pt 1):428-31
pubmed: 2381621
FASEB J. 2014 Oct;28(10):4183-99
pubmed: 25002120
J Clin Oncol. 2014 Oct 1;32(28):3111-7
pubmed: 25135988
Stat Med. 1989 May;8(5):551-61
pubmed: 2657958
Lancet. 2016 Mar 5;387(10022):945-956
pubmed: 26707054
Clin Cancer Res. 2016 Sep 15;22(18):4664-75
pubmed: 27060155
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457
pubmed: 28223433
J Ovarian Res. 2017 Mar 20;10(1):20
pubmed: 28320479
Am J Epidemiol. 1985 Jul;122(1):51-65
pubmed: 4014201
N Engl J Med. 1983 Oct 13;309(15):883-7
pubmed: 6310399
Hum Reprod. 1996 Sep;11(9):2022-5
pubmed: 8921084
J Reprod Med. 1997 Oct;42(10):617-24
pubmed: 9350014
Fertil Steril. 1998 Dec;70(6):1101-8
pubmed: 9848302